Breaking data on the efficacy and cost-effectiveness of an exclusive human milk diet for premature infants to be presented at the 2022 American Academy of Pediatrics National Conference.

Breaking data on the efficacy and cost-effectiveness of an exclusive human milk diet for premature infants to be presented at the 2022 American Academy of Pediatrics National Conference.

Duarte, California.And the October 7, 2022 /PRNewswire/- Prolacta Biological Sciences®, the world’s leading hospital provider of 100% human milk-based nutritional products for premature and critically ill infants, today announced that two separate studies on an exclusive human milk diet (EHMD) will be presented as poster presentations at the 2022 American Academy of Pediatrics National Conference (AAP) to be held October 7-11 in AnaheimCalifornia.

One study based on real-world data from seven hospitals in the United States demonstrates the efficacy and cost-effectiveness of EHMD for premature infants.

  • Implementation of an exclusive human milk diet for premature infants: a real experience in diverse neonatal intensive care units. EHMD is associated with improved outcomes for very low birth weight (VLBW) preterm infants in the neonatal intensive care unit (NICU).1-7 on me Sunday October 9 From Noon until 1 PM PSTAnd the Jenny FoxMD, MPH, of Children’s Hospital Richmond in Virginia Commonwealth University in Richmond, Virginia, will interact with attendees and answer questions about her research, which aims to correct the current lack of factual clinical data about the effectiveness and cost-effectiveness of EHMD. Label data was drawn from a virtual 2020 expert roundtable where NICU leaders from seven diverse US hospitals shared their policies and insights regarding EHMD with the goal of providing a model for other organizations wishing to establish EHMD in NICUs.

“These collaborative data fill in gaps in evidence-based medicine for neonatal intensive care unit leaders and provide support for the application of EHMD to very premature infants,” said Dr. Fox. “Our study provides further evidence that hospitals, regardless of their size and type, can incorporate EHMD to improve complications while reducing overall costs.”

Another study provides real-world data on the benefits of EHMD for premature babies born weighing less than 750 g.

  • Associations of an exclusive human milk diet with morbidity and mortality in ELBW infants born weighing 750 g: a meta-analysis of individual participant data. – EHMD has shown promising results in clinical trials to reduce health complications of prematurity in infants weighing less than 1,250 g compared to scissors based on cow’s milk or traditionally used premature infant formulas.2-5.7-9 A team of authors led by Sarah M ReyesD., PhD, scientific liaison at Prolacta for Human Milk and Clinical Research, performed a meta-analysis of published studies to examine whether this reduction in complications extends to the smallest very low birth weight (ELBW), those born under 750 g.

“EHMD performed well in ELBW-born infants weighing less than 750 grams compared to cow’s milk-based food products,” said Dr. Reyes. “Our study provides more evidence that a healthcare provider can feed EHMD to even the most vulnerable infants safely, effectively, and without compromise.” Dr. Reyes will be available to discuss the results, which were based on individual patient data, at Saturday October 8 From 5:15 PM to 6 PM PST.

“It is an honor to have been chosen to present our findings at the AAP National Conference. Evidence continues to grow that EHMD provides tangible short- and long-term benefits to our premature and critically ill patients. The world’s data is an important part of that overall picture” Melinda J ElliottD., MD, chief medical officer of Prolacta, a practicing neonatologist, and co-author of a meta-analysis of individual participant data.

Posters will be shown in Saturday October 8 And the Sunday October 9From 10 a.m. to 6 p.m. PT In Hall A in Anaheim Convention Center, Anaheim Marriott, Marquis Hall Center.

About human milk products

The main difference between cow’s milk and mother’s milk based products is the composition – particularly the bioactive ingredients that are unique to human milk. These include immunoglobulins, lactoferrin, milk fat globulin membranes, and a wide variety of prebiotics known as human milk oligosaccharides (HMOs), which are not readily synthesized and are therefore significantly reduced or missing from cow’s milk-based food products.10 Bioactivity is believed to support infants’ immunity, development, growth and long-term health.11

Prolacta nutritional products based on 100% human milk have the highest bioactivity in the human milk industry.12 Prolacta food products are pasteurized using the profiles specified by the US Food and Drug Administration (FDA) to ensure pathogen inhibition and the highest level of safety while retaining as much of the natural bioactivity of the milk as possible.12 Pasteurized Prolacta products with VAT retain a higher bioactivity than products treated using other methods, including retort sterilization and high temperature treatment (UHT).13, 14

About Prolacta Bioscience

Prolacta Bioscience® Inc. is a privately held global life sciences company dedicated to advancing the science of human milk to improve the health of critically ill premature infants. Prolacta nutritional products based on 100% human milk have been evaluated in more than 20 clinical studies published in peer-reviewed scientific journals. More than 80,000 premature babies have benefited from Prolacta nutritional products worldwide so far.15th Founded in 1999, Prolacta is the world’s leading provider of human milk-based nutritional products for hospital use and is exploring the therapeutic potential of human milk across a wide range of ailments. Prolacta maintains the industry’s most stringent quality and safety standards for screening, testing and processing human milk from donors. Prolacta operates the world’s first pharmaceutical-grade human milk processing facilities, and uses containerized pasteurization and a patented and FDA-reviewed manufacturing process to ensure pathogen inactivation while protecting the nutritional composition and bioactivity of its human milk-based products. Prolacta is a global company headquartered in Duarte, CaliforniaIt can be found online at www.prolacta.comon me TwitterAnd the InstagramAnd the FacebookAnd the LinkedIn.

Media contact:
Lauren Cosmont
[email protected]M
310-721-9444

references

1. Swanson, J., Becker, A., Fox, J., Horgan, M., Moores, R., Pardalos, J., Pinheiro, J., Stewart, D. and Robinson, T., 2022. System Exclusive human milk formula for premature infants: a real experience in diverse neonatal intensive care units. In: National Conference of the American Academy of Pediatrics.

2. Asaad M, Elliott MJ, Abraham J. Lower cost and improved feeding tolerance in VLBW infants fed an exclusively breastmilk diet. j pyrinatol. 2016; 36 (3): 216–220. doi: 10.1038/jp.2015.168.0000

3. Hair AB, Peluso AM, Hawthorne KM, et al. Beyond prevention of necrotizing enterocolitis: Improving outcomes with an exclusive human milk diet [published correction appears in Breastfeed Med. 2017;12(10):663]. Breastfeeding. 2016; 11 (2): 70-74. doi: 10.1089/bfm.2015.0134

4. Abrams SA, Schanler RJ, Lee ML, Rechtman DJ. Greater mortality and morbidity in very preterm infants fed a diet containing cow’s milk protein products. Breastfeeding. 2014; 9 (6): 281-285. doi: 10.1089/bfm.2014.0024

5. Cristofalo EA, Schanler RJ, Blanco CL, et al. Randomized trial of exclusive human milk versus preterm prematurity in extremely preterm infants. J Pediatric. 2013 Dec; 163 (6): 1592-1595 AH. doi: 10.1016/j.jpeds.2013.07.011. Epub 2013 Aug 20.

6. Agostoni C, Buonocore G, Carnielli VP, et al. Enteral nutrient supply for preterm infants: a commentary from the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2010 Jan; 50 (1): 85-91. doi: 10.1097/MPG.0b013e3181adaee0

7. Sullivan S, Schanler RJ, Kim JH, et al. An exclusively human milk diet is associated with a lower rate of necrotizing enterocolitis than a diet based on human milk and cow’s milk products. J Pediatric. 2010; 156 (4): 562-567 AH. doi: 10.1016/j.jpeds.2009.10.040

8. Associations of Reyes S. for an exclusive human milk diet with morbidity and mortality in ELBW infants born weighing 750 g: a meta-analysis of individual participant data. In: National Conference of the American Academy of Pediatrics. 2022.

9. Delaney Manthey E, Birx BH, Swanson Jr. Team-based implementation of an exclusive breast milk diet. Adv for newborn care. 2019; 19 (6): 460–467. doi: 10.1097/ANC.0000000000000676

10. Ballard O, Morrow AL. Composition of human milk: nutrients and bioactive factors. Pediatric Clean North AM. 2013; 60 (1): 49-74. doi: 10.1016/j.pcl.2012.10.002

11. Gila Diaz A, Arribas SM, Algara A, et al. A review of bioactive factors in human breast milk: a focus on prematurity. Nutrients. 2019; 11 (6): 1307. doi: 10.3390/no 11061307

12. Internal data.

13. Lima HK, Wagner-Gillspie M, Perrin MT, Fogelman AD. Bacteria and bioactivity in pasteurized and shelf-stable breast milk products. Currency Dev Notre. 2017; 1 (8): e001438. doi: 10.3945/cdn 117001438

14. Meredith Dennis L, Zou J, Gonatelliki E, Librilla CP, Underwood MA, Smillowitz JT. Composition and diversity of macronutrients, immunoglobulins, and human milk oligosaccharides in breast milk from nonprofit and commercial milk banks. J Home Lact. 2018; 34 (1): 120-129. doi: 10.1177/0890334417710635

15. The estimated number of preterm infants fed with Prolacta products from January 2007 to me December 2021; The data in the file.

Source: Prolacta Bioscience


#Breaking #data #efficacy #costeffectiveness #exclusive #human #milk #diet #premature #infants #presented #American #Academy #Pediatrics #National #Conference

Leave a Comment

Your email address will not be published. Required fields are marked *